Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Bipolar Disord. 2011 Jun;13(4):406-13. doi: 10.1111/j.1399-5618.2011.00936.x.
Dopamine transmission abnormalities have been implicated in the etiology of bipolar disorder (BPD). However, there is a paucity of receptor imaging studies in BPD, and little information is available about the dopamine system in BPD. Reuptake of synaptic dopamine by the dopamine transporter (DAT) is the principal mechanism regulating dopamine neurotransmission, and is often used as a marker for presynaptic dopamine function. This positron emission tomography (PET) study investigated whether DAT availability differed between BPD and healthy control subjects.
A total of 11 unmedicated BPD patients in either the euthymic or depressed phase and 13 closely matched healthy subjects underwent PET imaging with the DAT-selective radiotracer [(11) C]CFT and a structural magnetic resonance imaging (MRI) scan. Striatal binding potential (BP(ND) ) was estimated using the multilinear reference tissue model. Region of interest and analyses were conducted to test for differences in [(11) C]CFT BP(ND) between groups.
Unmedicated BPD subjects had significantly lower DAT availability relative to healthy controls in bilateral dorsal caudate.
The results of this study support the hypothesis that there are abnormalities in the dopaminergic system in BPD, and suggest that DAT availability may be related to the neuropathology of BPD. Future studies are needed to determine if DAT availability cycles with disease phase.
多巴胺传递异常与双相障碍(BPD)的病因有关。然而,BPD 的受体成像研究较少,关于 BPD 中的多巴胺系统的信息也很少。多巴胺转运体(DAT)对突触多巴胺的再摄取是调节多巴胺神经传递的主要机制,通常用作突触前多巴胺功能的标志物。这项正电子发射断层扫描(PET)研究调查了 BPD 患者和健康对照组之间 DAT 的可用性是否存在差异。
共有 11 名未接受药物治疗的 BPD 患者(处于缓解期或抑郁期)和 13 名匹配良好的健康受试者接受了多巴胺转运体选择性放射性示踪剂[(11)C]CFT 和结构磁共振成像(MRI)扫描的 PET 成像。使用多线性参考组织模型估计纹状体结合潜能(BP(ND))。进行了感兴趣区域和分析,以测试组间[(11)C]CFT BP(ND)的差异。
与健康对照组相比,未接受药物治疗的 BPD 受试者双侧背侧尾状核的 DAT 可用性明显降低。
这项研究的结果支持这样一种假设,即 BPD 中存在多巴胺能系统异常,并且表明 DAT 可用性可能与 BPD 的神经病理学有关。需要进一步的研究来确定 DAT 可用性是否与疾病阶段相关。